Cellular immunotherapy of cancer
The field of immunotherapy is currently one of the most promising developments in medical science now helping thousands of patients with cancer or autoimmune diseases. At KIA we have established a group engaging in the development of new ways to make the patient’s T cells capable of killing cancer cells and curing the patient using the chimeric antigen-receptor T cells (CAR T cells) method. The group works in close collaboration with the Morten Gjerstorff and Karsten Skjødt groups at IMM, SDU, and with professors Niels Abildgaard and Charlotte Nyvold at the Dept. of Hematology, OUH, and with other national groups headed by Inge-Marie Svane (CCIT-DK), Lars Rønn Olsen (DTU), Rasmus O. Bak (Aarhus University) and Bjarne Kuno Møller (Skejby Hospital). Among our international collaborators are Tudor Fulga (Oxford University) and one of the strongest groups in the field: the Marcela V. Maus group at Massachusetts’ General Hospital and Harvard University. Dr. Maus is adjunct professor at KIA.
Professor Torben Barington
Clinical Immunology, SDU
Klinisk Immunologisk afd.
J. B. Winsløws Vej 4, 5000 Odense
Members of the team
Mike Barnkob, MD, PhD, postdoc
Christian Nielsen, cand.scient. PhD
Kristina Fruerlund Rasmussen, MD, research associate
Lærke J. B. Brandt, pregraduate student
Anna Niedziella Merrison, pregraduate student
Julia Heiselberg, pregraduate student
Development of Chimeric Antigen Receptor T cells Targeting the B-cell Receptor Signaling Pathway.